TRVI Stock Forecast & Price Target

Trevi Therapeutics has demonstrated a solid financial foundation, highlighted by a substantial cash position of $194.9 million, which the company anticipates will sustain operations into 2028. The steady progress towards Phase 3 development of Haduvio for chronic cough conditions, coupled with promising trial results and a forecasted sales opportunity of approximately $1.5 billion in idiopathic pulmonary fibrosis (IPF) chronic cough alone, bolsters the company's growth potential. Additionally, the narrowing net loss of $11.8 million signifies improved financial health and operational efficiencies within the company.

Trevi Therapeutics Inc. reported a decrease in R&D expenses, reflecting a strategic wind-down of past clinical studies; however, this reduction raises concerns about the company's ability to advance its development programs effectively. Key risks to Trevi's outlook include potential delays or failures in the ongoing clinical development of Haduvio, competitive pressures from emerging therapies, and the need for additional capital prior to achieving profitability. Furthermore, with around 13% of shares held by a single institutional investor, there is a heightened risk associated with market volatility and dependence on specific developments, which could adversely affect the stock's value.